EUVIMEDEUVIMED entdecken
Open Access

Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications

Lennart Bohrmann, Doroteja Novak, Marko Kroselj, Raghuvir H Gaonkar, Francesca Porto, Melpomeni Fani, Petra Kolenc, Marko Anderluh, Rosalba Mansi

Theranostics · 29.07.2026 · 16 (15) · 8447-8460

DOI: 10.7150/thno.129327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, erschienen am 29.07.2026. Verfasst von Lennart Bohrmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. Hauptthemen laut MEDLINE: Receptor, Cholecystokinin B, Radiopharmaceuticals, Benzodiazepinones, Theranostic Nanomedicine. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiolabeled gastrin antagonists are emerging as a new tool for the diagnosis and treatment of cholecystokinin-2 receptor (CCK2R) expressing tumors such as medullary thyroid carcinoma and small cell lung cancer, overcoming limitations of agonist-based ligands. In this study, the CCK2R antagonist nastorazepide (Z-360) was used as a targeting scaffold in combination with either a peptidic (NPP) or a hydrophilic polysaccharide (NPS) linker and the chelators DOTA and DOTAGA, yielding four novel radioligands. These were evaluated alongside the reference minigastrin analogs DOTA-PP-F11 and DOTA-MGS5.

Methods

All ligands were synthetized via solid-phase peptide synthesis and labeled with In-111 and Lu-177. In vitro characterization included receptor affinity, hydrophilicity and cellular uptake in A431-CCK2R. In vivo biodistribution and imaging were performed in A431-CCK2R xenografts. [177Lu]Lu-DOTAGA-NPP was further assessed in a proof-of-concept therapy study and metabolic stability assays.

Results

111In-labeled antagonists showed 3-4-fold higher site recognition than [111In]In-DOTA-PP-F11 and nanomolar affinities comparable to the reference ligand. Among the tested ligands, [111In]In-DOTAGA-NPP demonstrated the highest cellular uptake (22.0 ± 0.2%), approximately twice that of the other ligands and moderately higher than [111In]In-DOTA-PP-F11 (16.2 ± 1.8%) after 4 h at 37 °C. In vivo, all 177Lu-labeled antagonists demonstrated high tumor uptake (range: 22.98 ± 7.04 - 29.00 ± 3.30% I.A./g tissue) with [177Lu]Lu-DOTAGA-NPP exhibiting the most favorable tumor-to-tissue ratios. Compared with [177Lu]Lu-DOTA-MGS5, [177Lu]Lu-DOTAGA-NPP showed rapid tumor accumulation with faster washout but reduced stomach exposure and high in vivo stability. Conclusion: [¹⁷⁷Lu]Lu-DOTAGA-NPP emerged as the most promising lead compound, combining high tumor uptake, favorable tumor-to-organ ratios, and excellent in vivo stability. Although no significant therapeutic efficacy was observed in the tested xenograft model, the results support [177Lu]Lu-DOTAGA-NPP as a promising lead for optimization. Overall, these findings highlight the potential of Z-360-based CCK2R antagonists as scaffolds for next-generation theranostic radioligands and support their development as alternatives to minigastrin-based tracers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cholecystokinin BRadiopharmaceuticalsBenzodiazepinonesTheranostic NanomedicineAnimalsHumansMiceCell Line, TumorLutetiumLigandsIndium RadioisotopesRadioisotopesTissue DistributionFemale

Stichwörter der Autor:innen

SPECT/CTcholecystokinin-2 receptor (CCK2R) antagonistsnastorazepidepeptide receptor radionuclide therapyradioligands

Substanzen

Receptor, Cholecystokinin BLutetiumLutetium-177LigandsRadiopharmaceuticalsBenzodiazepinonesIndium RadioisotopesRadioisotopes

Autor:innen und Institutionen

  • Division of Radiopharmaceutical Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
  • Division of Nuclear Medicine, University Medical Centre Ljubljana, Zaloška 7, 1000 Ljubljana, Slovenia.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia.

Zitieren

APA

Bohrmann, L., Novak, D., Kroselj, M., Gaonkar, R. H., Porto, F., Fani, M., Kolenc, P., Anderluh, M., & Mansi, R. (2026). Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications. Theranostics, 16(15), 8447-8460. https://doi.org/10.7150/thno.129327

Vancouver

Bohrmann L, Novak D, Kroselj M, Gaonkar RH, Porto F, Fani M, et al. Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications. Theranostics. 2026;16(15):8447-8460. doi:10.7150/thno.129327

BibTeX
@article{Bohrmann2026,
  author = {Bohrmann, Lennart and Novak, Doroteja and Kroselj, Marko and Gaonkar, Raghuvir H and Porto, Francesca and Fani, Melpomeni and Kolenc, Petra and Anderluh, Marko and Mansi, Rosalba},
  title = {Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications},
  journal = {Theranostics},
  year = {2026},
  volume = {16},
  number = {15},
  pages = {8447--8460},
  doi = {10.7150/thno.129327}
}
Kostenlos starten →